Pregledni rad

https://doi.org/10.37797/ig.41.1.3

Covid-19 in children

Diana Didović ; Zavod za infektivne bolesti djece, Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Andrea Nikčević ; Zavod za infektivne bolesti djece, Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Ivana Valenčak-Ignjatić orcid.org/0000-0003-1523-1031 ; Zavod za infektivne bolesti djece, Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Lorna Stemberger-Marić orcid.org/0000-0002-5002-3492 ; Zavod za infektivne bolesti djece, Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska; Medicinski fakultet Sveučilišta u Zagrebu, Hrvatska
Srđan Roglić orcid.org/0000-0002-4441-2600 ; Zavod za infektivne bolesti djece, Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska; Medicinski fakultet Sveučilišta u Zagrebu, Hrvatska

Sažetak

COVID-19 in children accounts for up to 8% of all the cases and is less severe than in adults. This could be an underestimation. A significant number of children are asymptomatic. Sympto-matic infection is hard to distinguish from other respiratory tract viral infections based on symp-toms and laboratory results. Anosmia is the only symptom in children that is highly suggestive of COVID-19. Infected children mostly have a positive household member. However, the role of children in SARS-CoV-2 transmission is still controversial. Data suggest that schoolchildren have a greater impact in SARS-CoV-2 transmission compared to younger children. Multisystem in-flammatory syndrome in children is a new entity reported since April 2020 and is considered a rare complication of SARS-CoV-2 infection. It occurs in previously healthy older children and adolescents presenting with multisystem involvement and elevated inflammatory markers. Most children respond well to immune-modifying therapy.
Treatment of COVID-19 in children is based solely on data received from adults and consists of supportive treatment and, in rare occasions, antiviral therapy (remdesivir), corticosteroids (dexa-methasone) and monoclonal antibodies (tocilizumab). Further studies in children are needed in order to better understand this disease. This article discusses clinical presentation and therapeutic options for COVID-19 in children.

Ključne riječi

SARS-CoV-2; children; COVID-19; multisystem inflammatory syndrome in children (MIS-C); paediatric multisystem inflammatory syndrome

Hrčak ID:

259116

URI

https://hrcak.srce.hr/259116

Datum izdavanja:

18.6.2021.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.807 *